In addition, the mTOR inhibitor NVP-BEZ235 and the PI3K-MTOR inhibitor PF-04691502 are currently being tested as new targeted drugs for NPC [90,91]. The gene discussed is MTOR; the disease is nasopharyngeal carcinoma.